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This study describes unpublished research on improving the solubility of benznidazole by the formation of an inclusion complex. The 
cyclodextrins selected were αCD, βCD, γCD, HPβCD, RMβCD and SBβCD. All complexes were obtained in solution, presenting 1:1 
stoichiometry according to the phase solubility diagram. The highest association constants were obtained with RMβCD and SBβCD, 
being selected for attainment of solid state complexes. These were characterized using XRD, SEM and dissolution test. The data 
obtained suggest the formation of complexes and indicate that these may provide a promising alternative way of developing solid 
doses of drug with suitable biopharmaceutical properties.
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INTRODUCTION
Chagas disease is an endemic disease caused by the protozoan 
Trypanosoma cruzi and is considered to be a serious medical and 
social problem in Latin America, affecting approximately 10 million 
individuals, with an additional 40 million at risk of infection.1,2
Although it is not the ideal drug of choice, owing to its low 
solubility and consequent high toxicity, benznidazole (BNZ), N-
benzyl-2-(2-nitroimidazol-1-yl) acetamide, is currently the only drug 
available for Chagas disease treatment.3 
Increased knowledge of the physicochemical characteristics of 
drugs and of more effective techniques for improving the biopharma-
ceutical properties of drugs enables new therapeutic alternatives to 
be developed more cheaply and more quickly than the introduction 
of a new molecule into the treatment. 
Several techniques, such as solid dispersion,4 sol-emulsion,5 
inclusion complexation and conjugation with water-soluble polymer 
or cyclodextrin have been developed to enhance the solubility of 
various drugs.6-11
The potential use of natural cyclodextrins (CDs) and their syn-
thetic derivatives has been extensively studied as a way of improving 
certain drug properties, such as solubility, stability and/or bioavail-
ability. The property of enhancing solubility may be explained by the 
formation of water-soluble inclusion complexes in which the hollow, 
truncated, cone-like CD structure encapsulates the hydrophobic drug 
molecules in the apolar interior. By contrast, the outer, hydrophilic 
region of the CD, enables solubilization through interaction with 
water molecules.12,13 
As yet few researchers have adopted technical approaches that aim 
to optimize the biopharmaceutical properties of BNZ and none of these 
have considered the development of a solid pharmaceutical form. Alter-
natives to a parenteral solution of BNZ found in the literature include 
the development of liposomes2,4 and obtention of a ruthenium complex, 
trans-[Ru(Bz)(NH3)4SO2](CF3SO3)2,
14 which alters the solubility of the 
compound and increases the effectiveness of the drug. However, no 
study involving BNZ has placed the drug in an inclusion complex, an 
approach that may hold promise for the development of a solid dosage 
form that is more appropriate than the one currently available.15
The purpose of this study was to improve the solubility and disso-
lution rate of BNZ in order to develop a promising solid oral delivery 
system. Firstly, a screening of six types of CDs was performed and 
their capacity of increasing the drug intrinsic solubility evaluated 
by the phase solubility studies, being three natural CDs (α, β and 
γ) and three modified βCDs [randomly methylated βCD (RMβCD), 
hydroxypropyl βCD (HPβCD) and sulfobutyl ether βCD (SBβCD)]. 
In a second phase, BNZ-CD binary systems were prepared in solid 
state. Only the two modified βCDs, RMβCD and SBβCD, which had 
the highest complex association constants for this phase. The solid 
state complexes were obtained using a variety of methods, includ-
ing physical mixing, kneading, freeze-drying and evaporation. The 
inclusion complexes obtained were characterized using X-ray powder 
diffraction (XRPD) and scanning electron microscopy (SEM), and 
the dissolution profile of the complex and the drug were determined.
EXPERIMENTAL 
Materials
The BNZ, N-benzyl-2-(2-nitroimidazol-1-yl) acetamide, was 
supplied by Roche. The purity was estimated using DSC and high 
performance liquid chromatography (HPLC) to be 99.9%. βCD and 
RMβCD (degree of molar substitution of 0.57) were donated by 
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Roquette (Barcelona, Spain); HPβCD (degree of molar substitution 
of 2.7) by Janssen Pharmaceutica (Beerse, Belgium) and SBβCD 
(degree of molar substitution of 1.0) by CyDex (Lenexa, KS). All 
other materials were of analytical grade. The solutions were prepa-
red using distilled water, filtered through 0.22 μm Millipore filters 
(Millipore Corp®, Billerica, MA).
Analytical methods
The UV spectrophotometric method was used, following the 
method previously reported by Soares-Sobrinho et al.16 for quantita-
tive determination of BNZ, on an Agilent 8453 UV-Visible spectro-
photometer (Agilent Corp, Santa Clara, CA) with a photodiode array 
detector set at 324 nm. The calibration curve in water was plotted 
using standard solutions in the range of 4 to 40 μg mL-1. The addition 
of CD’s was observed to have no effect on the UV spectrum of the 
BNZ solution for any of the CDs studied.
Phase solubility diagram 
Phase solubility studies were performed according to the method 
reported by Higuchi et al..17 Excess quantities of BNZ (~30 mg) 
were added to 5 mL aqueous solutions containing increasing con-
centrations of CDs, in the range of 0 to 1.5% (wt/vol) for βCD; 0 to 
2% (wt/vol) for α and γ CD; 0 to 4% (wt/vol) for HPβCD RMβCD 
and SBβCD. Suspensions were placed in an ultrasound bath for 
15 min and shaken in an oscillating water bath thermostatically 
controlled at 25 ºC for 7 days, which previous studies have shown 
to be sufficient time to ensure equilibrium. Samples were filtered 
and appropriately diluted. The concentration of BNZ was deter-
mined using a spectrophotometer. Experiments were performed in 
triplicate. The drug-CD association constants (K1:1) were calculated 
using the linear portion of the phase solubility diagrams, assuming 
1:1 stoichiometry, according to the Equation 1, where S0 is BNZ 
water solubility in the absence of CD:
   (1)
Preparation of solid-state complexes
Preparation of physical mixture
A physical mixture (PM) of BNZ and the CDs RMβCD or 
SBEβCD was obtained by mixing the compounds in a Turbula WAB 
T2C mixer (Willy A. Bachofen Corp, Basel, Switzerland) at a 1:1 
mol ratio for 25 min.
Preparation of kneaded systems (KN)
The kneaded system (KN) was prepared from the physical mixture 
in a mortar by the slow addition of ethanol/water (1:1 vol/vol), at 20% 
wt/wt, and mixed until a homogeneous system was obtained. Samples 
were dried for 24 h in a 40 ºC oven and powdered. 
Preparation of freeze-dried systems (FD)
The physical mixture was dissolved in ethanol:water (1:1 vol/
vol). The solution was frozen by immersion in liquid nitrogen and 
freeze-dried (FD) in a Labconco apparatus (Labconco Corp, Kansas 
City, MO). 
Evaporation (EV)
The physical mixture was dissolved in ethanol:water (1:1 vol/
vol). The solution was evaporated in a vacuum at 50 ºC in a rotary 
evaporator (Büchi Rotavapor R-200). 
The characterization of the solid-state complexes 
X-ray powder diffraction (XRPD)
The X-ray powder diffraction patterns were collected using co-
pper radiation (40 Kv, 30 mA), on a Philips PW 1729 diffractometer 
(Philips Corp, Netherlands) with Bragg-Brentano geometry, in the 
2<2θ<60 range with a step size of 0.02º and counting time of 2 s 
per step. 
Scanning electron microscopy (SEM)
The surface morphologies of samples were examined using a 
LEO-435VP scanning electron microscopy (Leica Microsystems, 
Cambridge, UK). Particles were fixed on a brass stub using double-
sided tape and vacuum coated gold.
Dissolution studies 
In vitro dissolution studies were performed in accordance with 
the Food and Drug Administration’s18 specifications for poorly 
soluble drugs. The United States Pharmacopeia19 dissolution two 
paddle apparatus (Turu Grau DT-6, Barcelona, Spain) set at 75 rpm 
and 37 ºC (± 0.5 ºC) was used. In order to ensure the Sink condition 
of the method and increase the specificity of the dissolution test, to 
show that this method is able to distinguish between different drug 
formulations, the recommended medium for poorly soluble drugs was 
selected: namely, sodium chloride : hydrochloride acid buffer pH 1.2, 
with a volume of 900 mL. Powdered samples of 50 mg of BNZ or 
equivalent amounts of each BNZ/CD system (particle size 50-200 
μm) were tested. Samples were collected at certain time intervals, 
filtered through cellulose filters, and the concentration of dissolved 
drug was determined by spectroscopy at 324 nm. Three replicates 
were tested for each binary system. The dissolution profiles were 
assessed and compared using dissolution efficiency at 15 and 20 min 
(DE15 and DE20) as the parameters.20 The statistical analysis of the 
DE20 was performed using one-way analysis of variance (ANOVA) 
followed by a least significant difference (LSD) test using Statgraph-
ics Plus Version 3.
RESULTS AND DISCUSSION 
Phase solubility diagram
In this paper, we have used a method to determinate the asso-
ciation constants of the inclusion complexes formed between BNZ 
and all CDs used, based on phase solubility studies (Figure 1). The 
improvement in solubility of the BNZ depended greatly on the type of 
CD. In all cases, the solubility of BNZ increased linearly as a function 
of CD concentration over the concentration range under study, with 
gradients lower than one. These diagrams can be classified as AL 
type and suggest a 1:1 mol:mol BNZ-CD stoichiometry, according 
to Higuchi et al..17 This drug had not hitherto been evaluated using 
studies involving CDs. 
The K1:1 values obtained for βCD and derivatives (HPβCD, 
RMβCD, SBβCD) were almost twice as high as those obtained for 
the other CDs (αCD and γCD) (Figure 1) (Table 1). The improved 
solubility of RMβCD may result from the presence of methyl groups, 
which can extend the hydrophobic region of the CD cavity, facilita-
ting and stabilizing BNZ inclusion complexation.21 A similar effect 
also occurs with the hydroxypropyl and sulfobutyl ether groups. All 
complex solutions had a final pH of ≈ 7.0, indicating no change in 
pH occurred during the study. 
As mentioned above, for a solid oral formulation it would be 
useful to select the CD derivatives (RMβCD, SBβCD) with the gre-
atest capacity for increasing BNZ solubility. Therefore, the general 
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characteristics of RMβCD and SBβCD, especially their high aqueous 
solubility and low toxicity, in addition to their greater capacity to 
dissolve BNZ, made these CDs the candidates for inclusion in an 
oral solid dosage form.22
Characterization of solid-state complexes
X-ray powder diffraction
XRPD was carried out on the samples in isolation (BNZ, RMβCD 
and SBβCD), PM and EV, FD and KN, with a view to identifying 
evidence of the formation of CD inclusion complexes (Figure 2). 
The diffractometric profile of the drug reveals the presence of high-
intensity peaks at 7.5, 16.5 and 22 º2θ, along with a number of secon-
dary peaks, thereby demonstrating the crystalline behavior of BNZ. 
The opposite can be seen in the diffratograms of the predominantly 
amorphous CDs. 
The PM method of preparation, both for RMβCD and SBβCD, 
correspond to the sum of both profiles with a reduction in the intensity 
of BNZ peaks owing to its concentration in the sample. It is possible, 
according to Figure 2, to identify alterations in some characteristic 
peaks of BNZ in addition to the disappearance or lower intensity of 
the other peaks in the processed preparations (KN, FD and EV). This 
may be taken as evidence of interaction between the components 
being facilitated by the processing of samples. 
Column 1 in Figure 2A shows the lower peak in the KN, FD and 
EV preparations, when compared to PM, along with the appearance of 
new peaks near the characteristic initial peak of BNZ at 7.5 ° 2θ. The 
appearance of new peaks not corresponding to the original component 
provides strong evidence of the formation of a new crystalline phase 
that may correspond to the drug-CD inclusion complex. 
Column 2 in Figure 2A points to the disappearance and weakening 
of peaks in the region between 20 and 26 2θ for the FD sample, which 
may indicate loss of crystalline structure in this sample, which can also 
be interpreted as evidence of interaction between BNZ and RMβCD. 
It was possible to detect small variations in the relative intensity 
of the peaks for the drug in mixtures containing SBβCD (Column 
3-4, Figure 2B) in the processed samples. However, these variations 
are difficult to interpret, since they may be caused by an effect of the 
preferred orientation of crystals. For the FD preparation (Figure 2B), 
a more pronounced amorphous profile can be seen, with alterations 
to the characteristics of the main crystalline peaks of the drug and, in 
the case of the preparation illustrated in Figure 2A, this may indicate 
interaction between components.
In view of these changes observed from the diffratograms, it is 
fair to say that there is consistent evidence of interaction and, conse-
quently, possible formation of inclusion complexes.23,24 
Scanning electron microscopy (SEM)
Morphological changes in particles can have an important impact 
on the dissolution profile.25,26 Selected photomicrographs of BNZ, 
RMβCD and SBβCD, along with those of binary systems processed 
are represented in Figure 3. BNZ characteristically takes the form of 
regular crystals,27 while RMβCD and SBβCD are normally composed 
of amorphous particles.8
In general, all the processed samples underwent changes in the 
morphology of the particles. The characteristics of the amorphous 
particles of the non-manipulated CDs were not observed. The KN 
preparation form aggregates (granules) that are somewhat uniform 
in size. The FD formulation of both CDs and the EV formulation of 
RMβCD show a reduction in the size of particles, which take the 
form of needles shaped completely differently from the materials at 
the start of the experiment. The change in shape and reduction in size 
of particles seems to less striking for the EV preparation of SBβCD. 
Dissolution studies 
The dissolution profiles for the systems under study are presented 
in Figure 4. The dissolution efficiency was calculated after 15 and 
20 min for all the products studied (Table 2). Data from the literature 
show that increases in the dissolution of inclusion complexes for 









Figure 2. X-ray diffraction patterns of BNZ with RMβCD (A) and SBbCD 
(B) as supplied and their processed binary systems
Figure 1. Phase solubility diagrams of BNZ as a function of cyclodextrin 
concentrations at 25 ºC in water. () HPbCD, () SBbCD, () RMbCD, 
() aCD, () γCD, () bCD
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different drugs can be explained by their higher energy amorphous 
state (reduction in crystallinity) and by the lower interfacial tension 
between water and the insoluble drug.25
Significant differences were observed in the dissolved quantities 
of pure drug (BNZ), PM and processed forms (KN, FD and EV) 
as well as in the dissolution rate. Five minutes after the start of the 
dissolution test, the percentage of drug dissolved was ≈12%; the 
percentage of drug dissolved from the RMβCD complex was over 
80% and the percentage of drug dissolved from the SBβCD complex 
was over 50%. 
In the case of both PMs, the dissolution efficiency brought about 
a significant difference in comparison to pure BNZ (p < 0.05). This 
appears to be a consequence of the mechanical treatment which in-
creases the contact between the drug and the carrier. This fact can be 
attributed to the improved wettability of PMs, owing to the presence 
of cyclodextrins,28 as well as, in the earlier stages of the dissolution 
process, CD molecules operating locally on the hydrodynamic layer 
surrounding the particles of BNZ. This results in an in situ inclusion 
process and produces a rapid increase in the amount of dissolved drug.29 
Although the kneading process is efficient in improving the dis-
solution rate for binary systems, as in the case of the BNZ-RMβCD 
complex, where ≈100% of the drug dissolved within 10 min of testing, 
the interaction with the drug requires a better method, such as the 
FD or EV, to obtain similar results for mixtures with SBβCD. These 
results may be explained by an intrinsic interaction between BNZ 
and RMβCD at surface level, as demonstrated by SEM (Figure 4), 
as this facilitates the formation of the complex.
The dissolution rates ranked as follows according to ANOVA: 
BNZ < PMSBβCD < PMRMβCD = KNSBβCD < KNRMβCD =FD 
= EV. These results suggest FD and EV should be the recommended 
Table 2. Calculated mean values of dissolution efficiency at 15 and 20 min
BNZ
PM KN FD EV
RMβCD SBβCD RMβCD SBβCD RMβCD SBβCD RMβCD SBβCD
%DE15min 12.4 (±1.2) 46.9 (±2.6) 28.8 (±3.7) 77.8 (±1.2) 48.7 (±2.1) 74.7 (±2.8) 76.1 (±2.0) 83.4 (±1.3) 75.8 (±1.3)
%DE20min 14.2 (±1.3) 54.4 (±1.9) 37.8 (±3.7) 81.8 (±1.1) 54.2 (±1.9) 81.0 (±1.7) 81.8 (±2.2) 87.6 (±1.8) 81.9 (±1.5)
Figure 3. Scanning electron microphotographs of BNZ; RMbCD; SBbCD; 
PM; KN, EV and FD systems
Figure 4. Dissolution profiles of BNZ, PM, KN, EV and FD systems with 
RMbCD and SBbCD, in sink condition. () BNZ, () PM, () KN, () 
FD, () EV
methods for preparation of inclusion complexes between BNZ and 
CDs with a higher solubilizing power. The KN method could also be 
used for BNZ:RMβCD binary mixtures, owing to the high capacity 
of CD to form inclusion complexes spontaneously.
CONCLUSION 
In conclusion, the βCD derivatives, SBβCD and RMβCD, can 
be shown to be highly efficient in terms of BNZ solubilization. The 
results suggest the possible formation of inclusion complexes using 
the EV, FD and KN techniques, with a dramatic improvement in drug 
dissolution rate compared to the drug alone or the CD/drug PM. The 
SEM and XRPD results obtained show that a BNZ:CDs inclusion 
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complex with a good dissolution profile could be prepared at a 1:1 
molar ratio using EV, FD and KN methods. In view of these results, 
we believe that complexation effectively enhanced the solubility of 
BNZ, which may consequently increase its bioavailability and might 
improve its pharmaceutical potential, providing a more uniform and 
efficient dissolution profile, minimizing variations during the drug 
solubilization stage, exposing the organism to lower quantities of the 
drug and hence lowering its toxicity.
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